Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC
NCT06178211Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Primary endpoint: Pathologic Complete Response Rate at 12 months. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06178211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178211.